Important Safety Information on CRYSVITA (burosumab) and the Risk of Severe Hypercalcemia in Patients with Tertiary Hyperparathyroidism
Critical priority
The issue
New safety information - Product safety
Affected product
CRYSVITA (burosumab)
Where it was sold
Canada (national)Reported in the official notice — confirm there.
Issued by
Health Canada — Marketed health products
Read the official Government of Canada notice
All recallsRecallGuardian ranks, illustrates and rewrites recalls in plain language. The official notice is authoritative — confirm model numbers, lot codes, dates and remedies there.